AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02590783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control intervention
Description: Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
Study NCT02689778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
Study NCT01613976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT00481507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
Study NCT00481507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pilocarpine
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02420782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral
Study NCT02618356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed and S-1
Description: Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d
Study NCT01789931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifebeam
Description: The lifebeam sensor will be attached to the participant's skin during the HTT.
Study NCT01030601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: 0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
Study NCT01059929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Study NCT01059929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Study NCT01059929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Study NCT01059929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
Study NCT02689778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets without active substance
Study NCT05190133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201602 and co-administration of UIC201601 and UIC201602
Description: * UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days
Study NCT05190133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201601 and co-administration of UIC201601 and UIC201602
Description: * UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days
Study NCT00042978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00042978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00042978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00042978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00042978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV
Study NCT03591419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polymer clip
Description: polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
Study NCT03591419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoloop
Description: endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
Study NCT06228989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restorative therapy
Description: Restorative treatment of first permanent molars affected with severe MIH
Study NCT06228989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction therapy
Description: Extraction treatment of first permanent molars affected with severe MIH
Study NCT04256200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest 2 MG Oral Tablet
Description: Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
Study NCT04256200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: 0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
Study NCT04820504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Infant Resuscitator (AIR)
Description: Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
Study NCT04820504 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AIR device without feedback
Description: Device provides no visual feedback to clinician but records data on ventilation effectiveness
Study NCT00580281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test, urine test, and bone density x-ray.
Description: start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
Study NCT04383678 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal membrane oxygenation
Description: Veno-venous or veno-arterial extracorporeal oxygenation
Study NCT02641821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance program
Description: Already in arm/group descriptions
Study NCT01848275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool®Rcatheter
Description: The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
Study NCT03027934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor, 90mg twice daily
Study NCT03027934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasurgrel, 10mg once daily
Study NCT01848275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool®Rcatheter
Description: The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance program
Description: Already in arm/group descriptions
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Airway clearance program
Description: Already in arm/group descriptions
Study NCT00485303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
Study NCT00485303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
Study NCT01785316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IHP
Study NCT00147238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10 (USPIO)
Description: Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
Study NCT00147238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR lymphangiography
Description: First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
Study NCT00147238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR lymphangiography
Description: First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
Study NCT00102973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLK286 in Combination with Carboplatin
Description: Experimental Arm
Study NCT00102973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin HCl Liposome Injection
Description: Active Comparator
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Study NCT03644888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration therapy
Description: Already in arm/group descriptions
Study NCT03644888 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibration therapy
Description: Already in arm/group descriptions
Study NCT03108911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard diet
Study NCT03108911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Provide stool sample
Study NCT03793543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Study NCT00590161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline (PTX)
Description: 400 mg PO tid
Study NCT00590161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tid
Study NCT05602428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine sub-anesthetic,
Description: the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
Study NCT05602428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine sub-anesthetic
Description: Esketamine subanesthetic dose combined with lumbar plexus block was used
Study NCT05602428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine sub-anesthetic
Description: general anesthesia was performed with esketamine subanesthetic dose.
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Study NCT03108911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive GFD
Study NCT03108911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01069536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide 10 mg
Study NCT00808171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livopan
Description: Inhalation of oxygen and nitrous oxide 50%
Study NCT00808171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livopan
Description: equimolar mixture of N2O/O2
Study NCT00808171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: Lidocaine-prilocain cream
Study NCT04396015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bulletproof Brain Octane
Description: Medium chain triglyceride oil (MCT)
Study NCT04396015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bulletproof Brain Octane
Description: Medium chain triglyceride oil (MCT)
Study NCT04396015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (olive) oil
Study NCT02216006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, conventional ventilatory settings
Description: Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Study NCT02216006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High fresh gas flow, high minute ventilation
Description: Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Study NCT05277779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance(CMR)
Description: CMR was performed to assess myocardial tissue characteristics in the study population
Study NCT02135263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10 mg as a single dose followed by blood samples for the next 33 hours
Study NCT02135263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 10 mg as a single dose followed by blood samples for the next 72 hours
Study NCT05088343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
Study NCT05088343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: 7.5 mg hetrombopag was administered on Day 6 to Day 11.
Study NCT03422653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.5 mcg/kg
Description: IV medication delivered three times/week
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Study NCT01970371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic of Investigator's choice
Study NCT02988609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
Study NCT02988609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
Study NCT03483103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lisocabtagene maraleucel
Description: lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
Study NCT00699751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
Study NCT00699751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline 6 IV administrations separated by 4 weeks intervals.
Study NCT00699751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best standard of care (BSoC)
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Study NCT00699751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best standard of care (BSoC)
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Study NCT00762905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LiquiBand Laparoscopic
Description: LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
Study NCT00762905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
Study NCT00756301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine local anesthesia- Alternative
Description: Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
Study NCT00756301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine local anesthesia- Alternative
Description: Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
Study NCT01348269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclasta
Description: 1 x intravenous non-current drip (infusion)
Study NCT01059929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical and Occupational Therapy
Description: Daily therapy sessions targeting range of motion, strength, and mobility
Study NCT00344890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: 1,2,3,or 4 level surgery
Study NCT00344890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: 1,2,3,or 4 level surgery
Study NCT02447705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: telbivudine replace Lamivudine
Study NCT01456910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Program
Description: Frequency, volume, repetitions, load, interval